Key Takeaways
- • Regeneron Pharmaceuticals announced a strategic research collaboration with Parabilis Medicines valued at $125 million in upfront and equity commitments, with up to $2.2 billion in additional milestone payments and tiered royalties.
- • The partnership combines Regeneron's VelocImmune®-derived antibody platform with Parabilis' proprietary Helicon™ peptide technology to develop Antibody-Helicon™ Conjugates (AHCs), a novel therapeutic class targeting intracellular and "undruggable" protein targets.
- • Regeneron's commitment structure includes $50 million upfront payment and $75 million equity investment, demonstrating significant confidence in Parabilis' cell-penetrant alpha-helical peptide technology as a differentiated approach to historically intractable drug targets.
- • The collaboration spans multiple therapeutic areas and positions both companies to create an entirely new drug class by coupling stabilized, cell-penetrant peptides to antibodies for precise intracellular delivery.
- • George D. Yancopoulos, Regeneron's Board co-Chair, President and Chief Scientific Officer, characterized the partnership as reflecting the company's strategy to advance "cutting-edge and diversified science" to build a robust innovative medicine portfolio.
Summary
Regeneron Pharmaceuticals has entered a strategic research collaboration with Parabilis Medicines centered on developing novel antibody-peptide conjugates designed to address historically challenging drug targets. The transaction, announced May 18, 2026, structures Regeneron's total commitment at $125 million, divided between a $50 million upfront payment and a $75 million equity investment in Parabilis, with potential milestone payments reaching approximately $2.2 billion alongside tiered royalties on commercialized products.
The collaboration leverages Parabilis' proprietary Helicon™ peptide platform—stabilized, cell-penetrant alpha-helical peptides capable of engaging intracellular protein targets—in combination with Regeneron's industry-leading antibody capabilities. The partnership specifically focuses on developing Antibody-Helicon™ Conjugates (AHCs), which represent a novel therapeutic class designed to target flat protein surfaces and intracellular binding sites that have traditionally resisted small molecule and conventional antibody approaches. The platform explores both standalone Helicon therapeutics and AHCs that couple Helicons to Regeneron's VelocImmune®-derived antibodies for precise cellular delivery.
According to Regeneron's Chief Scientific Officer George D. Yancopoulos, the collaboration exemplifies the company's commitment to advancing diversified, cutting-edge science. The strategic rationale centers on the potential to create an entirely new therapeutic class applicable across multiple disease areas by combining two complementary technologies: antibodies for target specificity and cellular recognition, and cell-penetrant peptides for intracellular engagement of previously undruggable targets. This partnership expands Regeneron's pipeline diversification beyond its core monoclonal antibody expertise into peptide conjugate therapeutics, positioning both companies at the intersection of emerging antibody and peptide innovation trends in the biopharmaceutical sector.
The collaboration leverages Parabilis' proprietary Helicon™ peptide platform—stabilized, cell-penetrant alpha-helical peptides capable of engaging intracellular protein targets—in combination with Regeneron's industry-leading antibody capabilities. The partnership specifically focuses on developing Antibody-Helicon™ Conjugates (AHCs), which represent a novel therapeutic class designed to target flat protein surfaces and intracellular binding sites that have traditionally resisted small molecule and conventional antibody approaches. The platform explores both standalone Helicon therapeutics and AHCs that couple Helicons to Regeneron's VelocImmune®-derived antibodies for precise cellular delivery.
According to Regeneron's Chief Scientific Officer George D. Yancopoulos, the collaboration exemplifies the company's commitment to advancing diversified, cutting-edge science. The strategic rationale centers on the potential to create an entirely new therapeutic class applicable across multiple disease areas by combining two complementary technologies: antibodies for target specificity and cellular recognition, and cell-penetrant peptides for intracellular engagement of previously undruggable targets. This partnership expands Regeneron's pipeline diversification beyond its core monoclonal antibody expertise into peptide conjugate therapeutics, positioning both companies at the intersection of emerging antibody and peptide innovation trends in the biopharmaceutical sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.